KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Accured Expenses: 2015-2025

Historic Change in Accured Expenses for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to $12.2 million.

  • CRISPR Therapeutics AG's Change in Accured Expenses rose 131.91% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year increase of 213.97%. This contributed to the annual value of -$27.3 million for FY2024, which is 34.75% down from last year.
  • CRISPR Therapeutics AG's Change in Accured Expenses amounted to $12.2 million in Q3 2025, which was up 182.82% from -$14.7 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Change in Accured Expenses peaked at $43.0 million during Q1 2025, and registered a low of -$38.2 million during Q3 2024.
  • Over the past 3 years, CRISPR Therapeutics AG's median Change in Accured Expenses value was -$7.8 million (recorded in 2024), while the average stood at -$641,545.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 2,040.74% in 2022, then slumped by 258.39% in 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Change in Accured Expenses (Quarterly) stood at $22.8 million in 2021, then slumped by 236.50% to -$31.1 million in 2022, then spiked by 70.44% to -$9.2 million in 2023, then grew by 14.59% to -$7.8 million in 2024, then soared by 131.91% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, -$14.7 million for Q2 2025, and $43.0 million during Q1 2025.